Policy | June 26, 2024
CCRAS hosts national consultative meet on traditional medicine
Signs MoUs with Shri Krishna Ayush University and Dabur India
Signs MoUs with Shri Krishna Ayush University and Dabur India
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Subscribe To Our Newsletter & Stay Updated
